ChemPartner PharmaTech Co., Ltd.

ChemPartner PharmaTech Co., Ltd. is a CRO that provides a wide range of support from early drug discovery to non-clinical development, and this report examines and summarizes the company's features, disease models it possesses, case studies, and other information.

Features of ChemPartner PharmaTech Co., Ltd.'s Contract Non-clinical Trial Services

Strengths in exploratory toxicology and biologics discovery

In addition to its headquarters in China, ChemPartner PharmaTech Co., Ltd. is based in San Francisco, USA,Strengths in chemistry, biology, pharmacology, DMPK (pharmacokinetics, metabolism), and exploratory toxicology and biologics discoveryWe are a global CRO (contract research organization) with

Along with providing services as a CRO, the company also serves as a partner to pharmaceutical and biotech companies to help them progress their projects. The company employs over 1,500 experienced scientists and pharmaceutical industry leaders educated in Europe and the United States to provide research and development services.

Support drug discovery and development programs

ChemPartner PharmaTech Co., Ltd.'s DMPK division has conducted over 80,000 ADME profiling and more than 50,000 exploratory toxicology studies since its establishment in 2007,Support drug discovery and development programs at partners worldwideThe company is a leading provider of services to the pharmacokinetic clientele. The company also provides services to pharmacokinetic clients.

Provision of IND application packages

The company has integrated DMPK/toxicity data to meet US FDA and NMPA regulatory requirements.IND application package providedWe are committed to Based on the hundreds of FDA filings we have handled, we provide strong support to our clients by preparing reports that meet the rigorous standards required by regulatory authorities (GLP/GCLP compliant ADMET packages).

An example of ChemPartner PharmaTech Co., Ltd.'s disease state model

The company offers a variety of in vivo disease models in the immunology and inflammation areas. For example, the company has developed theAdjuvant-induced arthritis (AIA) model in ratsThere is a In this model, female Lewis rats (weighing 180-200 g) are used to induce arthritis with CFA and to evaluate drug efficacy against human rheumatoid arthritis. In addition, BALB/c mice are used to evaluate inflammation and immune responseCon A-induced systemic inflammation modelWe also offer

ChemPartner PharmaTech Co., Ltd.'s non-clinical case studies

In vitro efficacy study using an in vivo xenograft model

This is a case study in which the company's antibody-drug conjugate (ADC), trastuzumab DM1 (T-DM1; a biosimilar of Cadusaila®), was synthesized and tested for in vitro efficacy in a xenograft model. In this case study,Study ADC formulation well tolerated at study dosesIt has been reported that

ChemPartner PharmaTech Co., Ltd. Company Information

In addition to its Shanghai headquarters, ChemPartner PharmaTech Co., Ltd., based in San Francisco, provides a wide range of support services from early drug discovery to non-clinical development. One of our unique features is that we provide support for the preparation of IND application packages based on our extensive experience.